Prisca Boisguérin

Physiologie et Médecine Expérimentale du Coeur et des Muscles

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

ÉV

Éric Vivès

Physiologie et Médecine Expérimentale du Coeur et des Muscles

Rudolf Volkmer

Charité - Universitätsmedizin Berlin

Sébastien Deshayes

Physiologie et Médecine Expérimentale du Coeur et des Muscles

Karidia Konate

Physiologie et Médecine Expérimentale du Coeur et des Muscles

Dean R. Madden

Dartmouth College

Bernard Lebleu

Université de Montpellier

Stéphanie Barrère‐Lemaire

Inserm

Patrick R. Cushing

Dartmouth College

Gudrun Aldrian

Université de Montpellier

Joël Nargeot

Institut de Génomique Fonctionnelle

Cooperative Institutions

Université de Montpellier

Centre National de la Recherche Scientifique

Inserm

Charité - Universitätsmedizin Berlin

Centre de Recherche en Biologie cellulaire de Montpellier

University of Oxford

Physiologie et Médecine Expérimentale du Coeur et des Muscles

University of Duisburg-Essen

Institut de Génomique Fonctionnelle

Centre Hospitalier Universitaire de Montpellier

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

In Vivo Follow-Up of Gene Inhibition in Solid Tumors Using Peptide-Based Nanoparticles for siRNA Delivery

Pharmaceutics (2021)

Isabel Ferreiro Coralie Genevois Karidia Konate Éric Vivès Prisca Boisguérin

Small interfering RNA (siRNA) exhibits a high degree of specificity for targeting selected genes. They are efficient on cells in vitro, but in vivo siRNA therapy remains a challenge for solid tumor treatment as siRNAs display difficulty reaching their intracellular target. The present study was designed to show the in vivo efficiency of a new peptide (WRAP5), able to form peptide-based nanoparticles (PBN) that can deliver siRNA to cancer cells in solid tumors. WRAP5:siRNA nanoparticles targeting firefly luciferase (Fluc) were formulated and assayed on Fluc-expressing U87 glioblastoma cells. The mode of action of WRAP5:siRNA by RNA interference was first confirmed in vitro and then investigated in vivo using a combination of bioluminescent reporter genes. Finally, histological analyses were performed to elucidate the cell specificity of this PBN in the context of brain tumors. In vitro and in vivo results showed efficient knock-down of Fluc expression with no toxicity. WRAP5:siFluc remained in the tumor for at least 10 days in vivo. Messenger RNA (mRNA) analyses indicated a specific decrease in Fluc mRNA without affecting tumor growth. Histological studies identified PBN accumulation in the cytoplasm of tumor cells but also in glial and neuronal cells. Through in vivo molecular imaging, our findings established the proof of concept for specific gene silencing in solid tumors. The evidence generated could be translated into therapy for any specific gene in different types of tumors without cell type specificity but with high molecular specificity.

Bioluminescence imaging

10.3390/pharmaceutics13050749

Cite

Citations (8)

Comparison of Cellular Uptake Using 22 CPPs in 4 Different Cell Lines

Bioconjugate Chemistry (2008)

Judith Mueller Ines Kretzschmar Rudolf Volkmer Prisca Boisguérin

Cell-penetrating peptides (CPPs) are short peptides able to penetrate cell membranes and translocate different cargoes into cells. Although recently the topic of many research articles, to our best knowledge no single systematic study of CPPs has been carried out as yet, meaning information can only by gathered piece by piece from different sources. We therefore decided to start analytical screening of CPP specificity in cell lines. We used 22 different CPPs, which have all been published before, and present the first analytical screen in 4 selected cell lines (MDCK, HEK293, HeLa, and Cos-7). Furthermore, we examined the influence of different conditions, such as protease inhibitors, incubation conditions, endocytosis inhibitors, temperature, and cytotoxicity. We clearly demonstrate that the 22 CPPs can be classified into 3 groups based on their internalization properties, even after trypsinization. Moreover, we show that additional agents, which should increase cellular uptake or dissolve endosomal/lysosomal entrapped CPPs, only have low effects. Our intensive screening under standardized conditions provides the opportunity to compare cellular uptake of CPPs, an important step for the use of CPPs as peptidic vectors in the medical field.

Trypsinization

Internalization

HeLa

Cell-penetrating peptide

HEK 293 cells

10.1021/bc800194e

Cite

Citations (186)

Quantification of PDZ Domain Specificity, Prediction of Ligand Affinity and Rational Design of Super-binding Peptides

Journal of Molecular Biology (2004)

Urs Wiedemann Prisca Boisguérin Rainer Leben Dietmar Leitner Gerd Krause

PDZ domain

Dissociation constant

Binding selectivity

10.1016/j.jmb.2004.08.064

Cite

Citations (139)

Using hydroxymethylphenoxy derivates with the SPOT technology to generate peptides with authentic C-termini

Bioorganic & Medicinal Chemistry Letters (2008)

Bernhard Aÿ Katja Landgraf Mathias Streitz Stephan Fuhrmann Rudolf Volkmer

10.1016/j.bmcl.2008.05.116

Cite

Citations (9)

Characterization of PDZ Domain/Ligand Specificity

Prisca Boisguérin

Title, Contents, Acknowledgements, Abbreviations 1\. General Introduction 2\. Materials and Methods 3\. Modification of the SPOT Synthesis Technique 4\. Analysis of Structure-Specificity-Relationships of PDZ 5\. A Novel PDZ Binding Motif 6\. Summary/Zusammenfassung 7\. References Appendix

PDZ domain

10.17169/refubium-6736

Cite

Citations (1)

Pharmacological stabilization of ΔF508-CFTR at the cell surface: design of CAL-selective PDZ inhibitors

Journal of Cystic Fibrosis (2010)

Patrick R. Cushing Prisca Boisguérin Lars Vouillème M. Pellegrini D.F. Mierke

PDZ domain

10.1016/s1569-1993(10)60055-0

Cite

Citations (0)

Mycobacterium abscessus alkyl hydroperoxide reductase C promotes cell invasion by binding to tetraspanin CD81

iScience (2023)

Jona Karam Fabien P. Blanchet Éric Vivès Prisca Boisguérin Yves‐Marie Boudehen

(

Tetraspanin

CD81

10.1016/j.isci.2023.106042

Cite

Citations (6)

Screening strategy to develop anticancer interfering peptides by SPOT synthesis

HAL (Le Centre pour la Communication Scientifique Directe) (2018)

Éric Vivès Sébastien Deshayes Chavey Bérengère Prisca Boisguérin Gudrun Aldrian

Source

Cite

Citations (0)

CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries

Current Pharmaceutical Design (2013)

Prisca Boisguérin Jean-Michel Giorgi Stéphanie Barrère‐Lemaire

Acute myocardial infarction (AMI) is a frequent and disabling disease, which is the first cause of cardiovascular mortality worldwide. Infarct size is a major determinant of myocardial functional recovery and mortality after AMI. Limitation of infarct size thus appears as an appropriate strategy to prevent post-ischemic heart failure and improve survival. Reperfusion is the only treatment recommended to reduce infarct size but despite obvious benefits, it may also have deleterious effects called ischemia-reperfusion (IR) injury including myocyte cell death. Proteins involved in the apoptosis cascade generally interact over large surfaces lacking well-defined pockets. Therefore, inhibitory peptides are optimal biomolecules to target these large protein surfaces, they are often more selective to their target than conventional small organic molecules, and they can be tailored for optimal affinity or desired metabolic property. Since peptides do not cross freely biological membranes, they are generally administered in association with cell penetrating peptides (CPPs) and with homing peptides (HPs) for selective organs or tissues targeting. As a first approach in vivo, we made use of the already known BH4 peptidic inhibitor of the mitochondrial apoptotic pathway, which showed cardioprotective properties in a murine model of AMI after a single bolus of intravenous administration. More importantly, similar peptidic strategies and tools are likely to be adaptable to many other situations in which cells have to be protected from apoptosis such as stroke or organ transplantation. Keywords: Anti-apoptotic peptide, ischemia-reperfusion, cell penetrating peptides, cardioprotection, systemic delivery, in vivo

Cardioprotection

Homing (biology)

Systemic administration

10.2174/1381612811319160011

Cite

Citations (19)

Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemia–reperfusion injuries in vivo

Journal of Controlled Release (2011)

Prisca Boisguérin Christelle Redt‐Clouet Alicia Franck-Miclo Sana Licheheb Joël Nargeot

Staurosporine

Cell-penetrating peptide

10.1016/j.jconrel.2011.07.037

Cite

Citations (41)